Publication List (Yukio Kato, Ph.D.)

November 24, 2025

1. Original articles 原著論文（*, corresponding author）

236) Wang H, Poulain S, Cao W, Arakawa H, Kim SH, Kato Y, Nishikawa M, Sakai Y, Leclerc E. Palmitic acid induced the onset of lipotoxicity in a HepaSH-on-chip model with raised of H2O2 and IL-6, and altered p38/MAPK & JAK/STAT pathways. Toxicology, 154345, 2025.

235) Suzuki, Ashukan; Noguchi, Saki; Tsuchitani, Toshiaki; Sakamoto, Ryo; Yamauchi, Aoi; Ishinabe, Takuro; Hashimoto, Ririka; Nakaguchi, Yoshimi; Sakai, Maiko; Imayoshi, Natsuki; Ishimoto, Takahiro; Kato, Yukio; Shirasaka, Yoshiyuki; Katakura, Satomi; Maruyama, Tetsuo; Nishimura, Tomohiro; Tomi, Masatoshi. Rat-specific expression of placental MATE1 contributes to species difference in fetal transfer of metformin and 1-methyl-4-phenylpyridinium. ***Mol Pharmaceut***, in press.
DOI: 10.1021/acs.molpharmaceut.5c00674

234) Kurniawan DA, Kanehara S, Osada Y, Mizuno A, Taniguchi H, Esashika K, Yang J, Yamasaki S, Masuo Y, Kato Y, Shiraki N, Kume S, Shinha K, Kimura H, Nishikawa M, Sakai Y. Bile acid transport and arachidonic acid influence hepatic CYP2D6 activity: Implications for drug metabolism in a gut-liver microphysiological system. ***Fundamental Toxicol Sci*** 12 (5): 135-141, 2025.
DOI: 10.2131/fts.12.135

233) Ohno Y, Yoshisue K, Masuo Y, Kato Y*. Construction of physiologically based pharmacokinetic model to predict CYP1A autoinduction by multi-kinase inhibitor TSU-68 based on in vitro induction kinetics. ***J Pharm Sci*** 114: 103953, 2025.
DOI: 10.1016/j.xphs.2025.103953

232) Shengyu D, Peng H, Kato Y, Arakawa H*. Role of organic anion transporter 2 in the efflux of raltegravir glucuronide from the endoplasmic reticulum in the liver. ***Biochem Pharmacol*** 242(Pt 1):117230, 2025.
doi: 10.1016/j.bcp.2025.117230 Accepted: August 11, 2025

231) Nishioka K, Ishimoto T, Katsube M, Yamada S, Araragi Y, Yamashita R, Kato Y*. Characteristics of ergothioneine distribution across skeletal muscles and adipose tissues. ***Biochem Biophys Res Commun*** 776: 152210. 2025.
DOI: 10.1016/j.bbrc.2025.152210 Accepted: June 13, 2025

230) Matsumoto N, Oishi A, Yoshino S, Masuo Y, Kubota Y, Ishida H, Shimada K, Kato Y, Fujita K*. *ABCC4* polymorphism indirectly reduces systemic exposure to a capecitabine metabolite 5'-deoxy-5-fluorouridine in Japanese subjects. ***Br J Clin Pharmacol*** 91(11):3092-3103, 2025.
DOI: 10.1002/bcp.70152 Accepted: June 8, 2025

229) Wang H, Meschini C, Poulain S , Kim SH, Arakawa H, Kato Y, Legallais C, Pereira U, Sakai Y, Leclerc E*. 3D hepatic spheroids and liver-organ on chip models displayed maintenance of hepatic functions and maturation profile in a long-term culture of the humanized HepaSH cells, a human cell population harvested from chimeric mice. ***Biotechnol Prog*** 41(5): e70043, 2025.
DOI: 10.1002/btpr.70043

228) Okumura H*, Araragi Y, Nishioka K, Yamashita R, Suzuki T, Watanabe H, Kato Y, Murayama N. Estimation and validation of an effective ergothioneine dose for improved sleep quality using physiologically-based pharmacokinetic model. ***Food Sci Nutr*** 13(6): e70382, 2025.
DOI: 10.1002/fsn3.70382 Accepted: May 23, 2025

228) Hanayama M, Ishimoto T, Moritomo A, Yamashita R, Kawai J, Mori K, and Kato Y*. Protective effects of Pleurotus species on UVB-induced skin disorders at clinically relevant plasma concentrations of the antioxidant ergothioneine in hairless mice. ***Biol Pharm Bull*** 48(5): 672-681, 2025.
DOI: 10.1248/bpb.b24-00893 Accepted: March 26, 2025

227) Ishimoto T, Hayashi F, Yamamoto Y, Kiriyama K, Yamashita R, Matsumura N, Nishiuchi T, Masuo Y, Fujita M, Sutoh K, Kato Y*. Trideoxycytidine diphosphate promotes neural stem cell proliferation and neurogenesis in mice. ***J Nutr*** 155(2):643-654, 2025.
DOI: 10.1016/j.tjnut.2024.12.021 Accepted: December 20, 2024

226) Wang H, Danoy M, Gong Y, Utami T, Arakawa H, Kato Y, Nishikawa M, Sakai Y, Leclerc E*. Palmitic acid induced a dedifferentiation profile at the transcriptome level: A collagen synthesis but

no triglyceride accumulation in hepatocyte-like cells derived from human-Induced pluripotent stem cells cultivated inside organ on a chip. ***J Appl Toxicol*** 45(3):460-471, 2025.
DOI: 10.1002/jat.4714

225) Mizuno S, Gake S, Takabayashi M, Ito Y, Sanada H, Sugimoto N, Maeda A, Tamamura T, Sawamoto K, Hara Y, Ohi Y, Tsuji C, Shiomoto Y, Kato Y, Fujita A, Shimada T, Miyamoto K, Sai Y*. Effect of obesity on pharmacokinetics of transdermal fentanyl: Single-center retrospective study and animal study. ***Drug Metab Pharmacokinet*** 60:101035, 2025.
DOI: 10.1016/j.dmpk.2024.101035

224) Nishioka K*, Ishimoto T, Sato M, Yasuda R, Nakamura Y, Watanabe H, Suzuki T, Araragi Y, Kato Y, Yoshida K, Murayama N. Optimizing oral 3-hydroxybutyrate dosage using pharmacokinetic model to enhance cognitive function and mood in healthy subjects. ***Front Nutr*** 11: 1470331, 2025.
DOI: 10.3389/fnut.2024.1470331

223) Mizuno, S., Takabayashi, M., Makihara, H. Ogai K, Tsukui K, Ito Y, Kawakami T, Hara Y, Fujita A, Tokudome Y, Akase T, Kato Y, Shimada T, Sai Y*. Effect of changes in skin properties due to diabetes mellitus on the titration period of transdermal fentanyl: single-center retrospective study and diabetic animal model study. ***J Pharm Health Care Sci*** 10(1): 80, 2024.
DOI: 10.1186/s40780-024-00402-5

222) Horiuchi S, Koda N, Ikeda Y, Tanaka Y, Masuo Y, Kato Y, Yamazaki D*. Examination of medium for co-culture of human hepatocytes and engineered heart tissue to evaluate cardiotoxicity associated with hepatic drug metabolism in vitro. ***Pros One*** 19(12): e0315997, 2024.
DOI: 10.1371/journal.pone.0315997

221) Watanabe N, Matsumoto S, Suzuki M, Fukaya T, Araragi Y, Fujihara R, Watanabe M, Kato Y, Hashiya N. (Japanese). Effect of ergothioneine on the stress-induced mood states, stomoch discomfort, and sleep quality in healthy volunteers experiencing stress. ***Jpn Pharmacol Ther*** 52(11): 1319-1335, 2024. 渡邉憲和、松本 聡、鈴木 真、深谷泰亮、蘭　雄大、藤原里帆、渡辺真紀、加藤将夫、橋弥尚孝　ストレスを感じる健常者に対するエルゴチオネイン含有食品のストレスによる気分状態、胃の不快感および睡眠の質改善効果—プラセボ対照ランダム化二重盲検並行群間比較試験—薬理と治療 52(11): 1319-1335, 2024.

220) Ishimoto T, Nakamichi N, Taguchi T, Nishiyama M, Kato Y*. Functional expression of carnitine/organic cation transporter 1 in murine choroid plexus. ***Biol Pharm Bull*** 47(9):1484-1486, 2024.
DOI: 10.1248/bpb.b24-00451

219) Chierico FD, Masi L, Petito V*, Baldelli V, Puca P, Benvenuto R, Fidaleo M, Palucci I, Lopetuso LR, Caristo ME, Carrozza C, Giustiniani MC, Nakamichi N, Kato Y, Putignani L, Gasbarrini A, Pani G, Scaldaferri F. The solute transporter OCTN1/Slc22a4 affects disease severity and response to Infliximab in experimental colitis: role of gut microbiota and immune modulation. ***Inflamm Bowel Dis***, 30(12): 2259-2270, 2024.
DOI: 10.1093/ibd/izae135

218) Ueno M, Sugiyama H, Li F, Nishimura T, Arakawa H, Chen, Cheng X, Takeuchi S, Takeshita Y, Takamura T, Miyagi S, Toyama T, Soga T, Masuo Y, Kato Y, Nakamura H, Tsujiguchi H, Hara A, Tajima A, Noguchi-Shinohara M, Ono K, Kurayoshi K, Kobayashi M, Tadokoro Y, Kasahara A, Shoulkamy MI, Maeda K, Ogoshi T, Hirao A*. A supramolecular biosensor for rapid and high-throughput quantification of a disease-associated niacin metabolite. ***Anal Chem*** 96(36): 14499-14507, 2024.
DOI: 10.1021/acs.analchem.4c02653

217) Arakawa H*, Ishida N, Nakatsuji T, Matsumoto N, Imamura R, Shengyu D, Araya K, Horike S, Tanaka-Yachi R, Kasahara M, Yoshioka T, Sumida Y, Ohmiya H, Daikoku T, Wakayama T, Nakamura K, Fujita K, Kato Y*. Endoplasmic reticulum transporter OAT2 regulates drug metabolism and interaction. ***Biochem Pharmacol*** 225: 116322, 2024.
DOI: 10.1016/j.bcp.2024.116322

216) Hanayama M*, Mori K, Ishimoto T, Kato Y, Kawai J. Effects of an ergothioneine-rich *Pleurotus* sp. on skin moisturizing functions and facial conditions; a randomized, double-blind, placebo-controlled trial. ***Front Med*** 11:1396783, 2024.
DOI: 10.3389/fmed.2024.1396783

215) Imamura R, Sugimoto M, Horike S, Fujita K, Tamai I, Daikoku T, Kato Y, Arakawa H*. Role of organic anion transporter NPT4 in renal handling of uremic toxin 3-indoxyl sulfate. ***J Pharm Sci*** 113(7): 1996-2000, 2024.
DOI: 10.1016/j.xphs.2024.04.014

214) Katsube M, Ishimoto T, Fukushima Y, Kagami A, Shuto T, and Kato Y*. Ergothioneine promotes longevity and healthy aging in male mice. ***GeroScience*** 46(4): 3889-3909, 2024.
DOI: 10.1007/s11357-024-01111-5

213) Scheidecker B*, Poulain S, Sugimoto M, Kido T, Kawanishi T, Miyajima A, Kim SH, Arakawa H, Kato Y, Nishikawa M, Danoy M, Sakai Y*, Leclerc E. Dynamic, IPSC-derived hepatic tissue tri-culture system for the evaluation of liver physiology in vitro. ***Biofabrication*** 16(2), 2024.
DOI: 10.1088/1758-5090/ad30c5

212) Kurniawan DA, Leo S, Inamatsu M, Funaoka S, Aihara T, Mizuno A, Inoue R, Sakura T, Arakawa H, Kato Y, Matsugi T, Esashika K, Shiraki N, Kume S, Shinha K, Kimura H, Nishikawa M, Sakai Y*. Gut-liver microphysiological systems revealed potential crosstalk mechanism modulating drug metabolism. ***PNAS Nexus*** 3(2): 070, 2024.
DOI: 10.1093/pnasnexus/pgae070

211) Ishimoto T, Yamashita R, Matsumoto R, Matsumoto S, Matsuo Y, Nakao S, Masuo Y, Suzuki M, Kato Y*. TrkB phosphorylation in serum extracellular vesicles correlates with cognitive function enhanced by ergothioneine in humans. ***NPJ Sci Food*** 8(1): 11, 2024.
doi: 10.1038/s41538-024-00250-5

210) Kimura T*, Okada K, Morohashi Y, Kato Y, Mori M, Kato H, Matsumoto T, Shimoyama S. Quantification of unencapsulated drug in target tissues demonstrates pharmacological properties and therapeutic effects of liposomal topotecan (FF-10850). ***Pharm Res*** 41(4): 795-806, 2024.
DOI: 10.1007/s11095-023-03652-4

209) Scheidecker B, Poulain S, Sugimoto M, Arakawa H, Kim SH, Kawanishi T, Kato Y, Danoy M, Nishikawa M, Sakai Y*. Mechanobiological stimulation in organ-on-a-chip systems reduces hepatic drug metabolic capacity in favor of regenerative specialization. ***Biotechnol Bioeng*** 121(4): 1435-1452, 2024.
DOI: 10.1002/bit.28653

208) Utami T, Danoy M, Khadim RR, Tokito F, Arakawa H, Kato Y, Kido T, Miyajima A, Nishikawa M, Sakai Y*. A highly efficient cell culture method using oxygen-permeable PDMS-based honeycomb microwells produces functional liver organoids from human induced pluripotent stem cell-derived carboxypeptidase M liver progenitor cells. ***Biotechnol Bioeng*** 121(4): 1178-1190, 2024.
DOI: 10.1002/bit.28640

207) Arakawa H, Kawanishi T, Shengyu D, Nishiuchi T, Meguro-Horike M, Horike S, Sugimoto M, Kato Y*. Renal pharmacokinetic adaptation to cholestasis causes increased nephrotoxic drug accumulation by Mrp6 downregulation in mice. ***J Pharm Sci*** 112(12): 3209-3215, 2023.
DOI: 10.1016/j.xphs.2023.08.008

206) Park AG, Fukasawa K, Horie T, Masuo Y, Inaba Y, Tatsuno T, Yamada T, Tokumura K, Iwahashi S, Iezaki T, Kaneda K, Kato Y, Ishigaki Y, Mieda M, Tanaka T, Ogawa K, Ochi H, Sato S, Shi Y, Inoue H, Lee H, Hinoi E*. L-type amino acid transporter 1 in hypothalamic neurons in mice maintains energy and bone homeostasis. ***JCI Insight***, 8(7): e154925, 2023.
DOI: 10.1172/jci.insight.154925

205) Alshammaria AH, Masuo Y, Yoshino S, Yamashita R, Ishimoto T, Fujita K, Kato Y*. Adeno-associated virus-mediated knockdown demonstrates the major role of hepatic Bcrp in the overall disposition of the active metabolite of the tyrosine kinase inhibitor regorafenib in mice. ***Drug Metab Pharmacokinet*** 49:100483, 2023.
DOI: 10.1016/j.dmpk.2022.100483

204) Tao F, Hanada S, Matsushima K, Arakawa H, Ishida N, Kato Y, Okimura S, Watanabe T, Kojima N*. Enhancement and maintenance of hepatic metabolic functions by controlling 3D aggregation of cryopreserved human iPS cell-derived hepatocyte-like cells. ***J Biosci Bioeng*** 135(2): 134-142, 2023.
DOI: 10.1016/j.jbiosc.2022.10.006

203) Matsumoto T, Masuo Y, Tanaka A, Kimura T, Ioroi T, Yamakawa T, Kitahara H, Kato Y*. A physiologically based pharmacokinetic and pharmacodynamic model for disposition of FF-10832. ***Int J Pharm*** 627: 12225, 2022.

DOI: 10.1016/j.ijpharm.2022.122250

202) Danoy M, Scheidecker B, Arakawa H, Esashika K, Ishida N, Ito H, Yanai H, Takahashi J, Nishikawa M, Kato Y, Sakai Y*. Cryopreserved human hepatocytes culture optimization on polymethylpentene oxygen permeable membranes for drug screening purposes. ***Fundam Toxicol Sci*** 9(4): 135-144, 2022.
DOI: https://doi.org/10.2131/fts.9.135

201) Katsube M*, Watanabe H, Suzuki K, Ishimoto T, Tatebayashi Y, Kato Y, Murayama N. Food-derived antioxidant ergothioneine improves sleep difficulties in humans. ***J Functional Foods*** 95: 105165, 2022.
DOI: https://doi.org/10.1016/j.jff.2022.105165

200) Nishikawa M, Ito H, Tokito F, Hirono K, Inamura K, Scheidecker B, Danoy M, Kawanishi T, Arakawa H, Kato Y, Esashika K, Miyasako H, Sakai Y*. Accurate evaluation of hepatocyte metabolisms on a noble oxygen-permeable material with low sorption characteristics. ***Front Toxicol*** 4: 810478, 2022.
DOI: 10.3389/ftox.2022.810478

199) Alshammari AH, Masuo Y, Fujita K, Iida N, Shimada K, Wakayama T, Kato Y*. Discrimination of hand-foot skin reaction of tyrosine kinase inhibitors based on direct keratinocytes toxicity and vascular endothelial growth factor receptor-2 inhibition. ***Biochem Pharmacol*** 197: 114914, 2022.
DOI: 10.1016/j.bcp.2022.114914

198) Matsukawa T, Mizutani S, Matsumoto K, Kato Y, Yoshihara M, Shibata K, Kajiyama H*. Placental leucine aminopeptidase as a potential specific urine biomarker for invasive ovarian cancer. ***J Clin Med*** 11(1), 222, 2021.
DOI: 10.3390/jcm11010222

197) Danoy M*, Tauran Y, Poulain S, Jellali R, Bruce J, Leduc M, Le Gall M, Koui Y, Arakawa H, Gilard F, Gakiere B, Kato Y, Plessy C, Kido T, Miyajima A, Sakai Y, Leclerc E*. Investigation of the hepatic development in the coculture of hiPSCs-derived LSECs and HLCs in a fluidic microenvironment. ***APL Bioeng*** 5(2): 026104, 2021.
DOI: 10.1063/5.0041227

196) Makiishi S, Furuichi K, Yamamura Y, Sako K, Shinozaki Y, Toyama T, Kitajima S, Iwata Y, Sakai N, Shimizu M, Hirose-Sugiura T, Kaneko S, Kato Y, Wada T*. Carnitine/organic cation transporter 1 precipitates the progression of interstitial fibrosis through oxidative stress in diabetic nephropathy in mice. ***Sci Rep*** 11(1):9093, 2021.
DOI: 10.1038/s41598-021-88724-4

195) Iida N, Yamashita T, Yutani M, Seishima J, Wang Z, Arai K, Okada H, Yamashita T, Sakai Y, Masuo Y, Agustina R, Kato Y, Fujinaga Y, Oshima M, Honda M, Lebreton F, Gilmore MS, Kaneko S*. Chronic liver disease enables gut *Enterococcus faecalis* colonization to promote liver carcinogenesis. ***Nat Cancer*** 2(10): 1039-1054, 2021.
DOI: 10.1038/s43018-021-00251-3

194) de Heredia ML, Muñoz L, Carru C, Sotgia S, Zinellu A, Serra C, Llebaria A, Kato Y, Nunes V*. S-methyl-L-ergothioneine to L-ergothioneine ratio in urine is a marker of cystine lithiasis in a cystinuria mouse model. ***Antioxidants*** 10(9): 1424, 2021.
DOI: 10.3390/antiox10091424

193) Shinha K, Nihei W, Nakamura H, Goto T, Kawanishi T, Ishida N, Yamazaki N, Imakura Y, Mima S, Inamura K, Arakawa H, Nishikawa M, Kato Y, Sakai Y, Kimura H*. A kinetic-pump integrated microfluidic plate (KIM-Plate) with high usability for cell culture-based multi-organ microphysiological systems. ***Micromachines*** 12(9): 1007, 2021.
DOI: 10.3390/mi12091007

192) Agustina R, Masuo Y, Kido Y, Shinoda K, Ishimoto T, Kato Y*. Identification of food-derived isoflavone sulfates as inhibition markers for intestinal breast cancer resistance proteins. ***Drug Metab Dispos***, 49(11): 972-984, 2021.
DOI: 10.1124/dmd.121.000534

191) Danoy M, Tauran Y, Poulain S, Jellali R, Bruce J, Leduc M, Gall ML, Gilard F, Kido T, Arakawa H, Araya K, Mori D, Kato Y, Kusuhara H, Plessy C, Miyajima A, Sakai Y, Leclerc E*. Multi-omics analysis of hiPSCs-derived HLCs matured on-chip revealed patterns typical of liver regeneration. ***Biotechnol Bioeng*** 118(10): 3716-3732, 2021.

DOI: 10.1002/bit.27667

190) Sako K, Nakamaru Y, Ikawa K, Maeda T, Goto S, Ishihara Y, Kato Y, Matsuda Y*. Population Pharmacokinetics and dosing optimization of teicoplanin in neutropenic patients with hematological malignancies. ***Ther Drug Monit*** 43(4): 519-526, 2021.
DOI: 10.1097/FTD.0000000000000906

189) Matsumoto T*, Komori T, Yoshino Y, Ioroi T, Kitahashi T, Kitahara H, Ono K, Higuchi T, Sakabe M, Kori H, Kano M, Hori R, Kato Y, Hagiwara S. A liposomal gemcitabine, FF-10832, improves plasma stability, tumor targeting, and antitumor efficacy of gemcitabine in pancreatic cancer xenograft models. ***Pharm Res*** 38(6): 1093-1106, 2021.
DOI: 10.1007/s11095-021-03045-5

188) Shinohara M, Arakawa H, Oda Y, Shiraki N, Sugiura S, Nishiuchi T, Satoh T, Iino K, Leo S, Kato Y, Araya K, Kawanishi T, Nakatsuji T, Mitsuta M, Inamura K, Goto T, Shinha K, Nihei W, Komori K, Nishikawa M, Kume S, Kato Y, Kanamori T, Sakai Y, Kimura H*. Coculture with hiPS-derived intestinal cells enhanced human hepatocyte functions in a pneumatic-pressure-driven two-organ microphysiological system. ***Sci Rep*** 11(1): 5437, 2021.
DOI: 10.1038/s41598-021-84861-y
DOI: 10.1038/s41598-021-84861-y

187) Futatsugi A, Masuo Y, Kato Y*. Effects of probenecid on hepatic and renal disposition of hexadecanedioate, an endogenous substrate of organic anion transporting polypeptide 1B in rats. ***J Pharm Sci*** 110(5): 2274-2284, 2021.
DOI: 10.1016/j.xphs.2021.02.011

186) Nakamichi N, Nakao S, Nishiyama M, Takeda Y, Ishimoto T, Masuo Y, Matsumoto A, Suzuki M, and Kato Y*. Oral administration of the food derived hydrophilic antioxidant ergothioneine enhances object recognition memory in mice. ***Curr Mol Pharmacol*** 14(2): 220-233, 2021.
DOI: 10.2174/1874467213666200212102710

185) Masuo Y, Fujita K, Mishiro K, Seba N, Kogi T, Okumura H, Matsumoto N, Kunishima M, and Kato Y*. 6-Hydroxyindole is an endogenous long-lasting OATP1B1 inhibitor elevated in renal failure patients. ***Drug Metab Pharmacokinet*** 35(6): 555-562, 2020.
DOI: 10.1016/j.dmpk.2020.09.001

184) Nishiyama M, Nakamichi N, Yoshimura T, Masuo Y, Komori T, Ishimoto T, Matsuo JI, Kato Y*. Homostachydrine is a xenobiotic substrate of OCTN1/SLC22A4 and potentially sensitizes pentylenetetrazole-induced seizures in mice. ***Neurochem Res*** 45(11): 2664-2678, 2020.
DOI: 10.1007/s11064-020-03118-8

183) Arakawa H, Yamada H, Arai K, Kawanishi T, Nitta N, Shibata S, Matsumoto E, Yano K, Kato Y, Kumamoto T, Aoki I, Ogihara T*. Possible utility of peptide-transporter-targeting [^{19}F]dipeptides for visualization of the biodistribution of cancers by nuclear magnetic resonance imaging. ***Int J Pharm*** 586 (2020) 119575.
DOI: 10.1016/j.ijpharm.2020.119575

182) Taguchi T, Masuo Y, Futatsugi A, Kato Y*. Static model-based assessment of OATP1B1-mediated drug interactions with preincubation-dependent inhibitors based on inactivation and recovery kinetics. ***Drug Metab Dispos*** 48(9): 750-758, 2020.
DOI: 10.1124/dmd.120.000020

181) Yoshitani J, Kabata T, Arakawa H, Kato Y, Nojima T, Hayashi K, Tokoro M, Sugimoto N, Kajino Y, Inoue D, Ueoka K, Yamamuro Y, Tsuchiya H*. Combinational therapy with antibiotics and antibiotic-loaded adipose-derived stem cells reduce abscess formation in implant-related infection in rats. ***Sci Rep*** 10(1): 11182, 2020.
DOI: 10.1038/s41598-020-68184-y

180) Danoy M, Poulain S, Tauran Y, Arakawa H, Mori D, Kido T, Kusuhara H, Araya K, Kato Y, Miyajima A, Plessy C, Sakai Y, Leclerc E*. Analysis of hiPSCs differentiation toward hepatocyte-like cells upon extended exposition to oncostatin. ***Differentiation*** 114: 36-48, 2020.
DOI: 10.1016/j.diff.2020.05.006

179) Watanabe N, Matsumoto S, Suzuki M, Fukaya T, Kato Y, Hashiya N. Effect of ergothioneine on the cognitive function improvement in healthy volunteers and mild cognitive impairment subjects: A randomized double-blind parallel-group comparison study (Japanese). ***Jpn Pharmacol Ther*** 48(4): 685-697, 2020.

渡邉憲和、松本 聡、鈴木 真、深谷泰亮、加藤将夫、橋弥尚孝　健常者および軽度認知障害者に対するエルゴチオネイン含有食品の認知機能改善効果—ランダム化プラセボ対照二重盲検並行群間比較試験—薬理と治療 48(4): 685-697, 2020.

178) Sarashina A, Chiba K, Tatami S, Kato Y*. Physiologically based pharmacokinetic model of the DPP-4 inhibitor linagliptin to describe its nonlinear pharmacokinetics in humans. ***J Pharm Sci*** 109(7): 2336-2344, 2020.
DOI: 10.1016/j.xphs.2020.03.031

177) Kubota Y, Fujita K, Takahashi T, Sunakawa Y, Ishida H, Hamada K, Ichikawa W, Tsunoda T, Shimada K, Masuo Y, Kato Y, Sasaki Y*. Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients. ***Clin Pharmacol Ther*** 108(3): 586-595, 2020.
DOI: 10.1002/cpt.1810

176) Arakawa H, Sugiura S, Kawanishi T, Shin K, Toyoda H, Satoh T, Sakai Y, Kanamori T, Kato Y*. Kinetic analysis of sequential metabolism of triazolam and its extrapolation to humans using an entero-hepatic two-organ microphysiological system. ***Lab on a Chip*** 20(3), 537-547, 2020.
DOI: 10.1039/c9lc00884e

175) Takahashi Y, Zhou Y, Miyamoto T, Higashi H, Nakamichi N, Takeda Y, Kato Y, Korchev YE, Fukuma T*. High-speed SICM for the visualization of nanoscale dynamic structural changes in hippocampal neurons. ***Anal Chem*** 92(2): 2159-2167, 2020.
DOI: 10.1021/acs.analchem.9b04775

174) Miyake T, Mizuno T, Takehara I, Mochizuki T, Kimura M, Matsuki S, Irie S, Watanabe, Kato Y, Ieiri I, Maeda K, Ando O, Kusuhara H*. Elucidation of N^1-methyladenosine as a potential surrogate biomarker for drug interaction studies involving renal organic cation transporters. ***Drug Metab Dispos*** 47(11): 1270-1280, 2019.
DOI: 10.1124/dmd.119.087262

173) Hashimoto N, Nakamichi N, Nanmo H, Kimura K, Masuo Y, Sakai Y, Schinkel AH, Sato S, Soga T, Kato Y*. Metabolome analysis reveals dermal histamine accumulation in murine dermatitis provoked by genetic deletion of P-glycoprotein and breast cancer resistance protein. ***Pharm Res*** 36(11): 158, 2019.
DOI: 10.1007/s11095-019-2695-3

172) Taguchi T, Masuo Y, Sakai Y, Kato Y*. Short-lasting inhibition of hepatic uptake transporter OATP1B1 by tyrosine kinase inhibitor pazopanib. ***Drug Metab Pharmacokinet*** 34(6): 372-379, 2019.
DOI: 10.1016/j.dmpk.2019.08.001

171) Nakamichi N, Matsumoto Y, Kawanishi T, Ishimoto T, Masuo Y, Horikawa M, Kato Y*. Maturational characterization of mouse cortical neurons three-dimensionally cultured in functional polymer FP001-containing medium. ***Biol Pharm Bull*** 42(9): 1545-1553, 2019.
DOI: 10.1248/bpb.b19-00307

170) Kawanishi T, Arakawa H, Masuo Y, Nakamichi N, Kato Y*. Bile duct obstruction leads to increased intestinal expression of breast cancer resistance protein with reduced gastrointestinal absorption of imatinib. ***J Pharm Sci*** 108(9): 3130-3137, 2019.
DOI: 10.1016/j.xphs.2019.05.017

169) Iwase M, Fujita K, Nishimura Y, Seba N, Masuo Y, Ishida H, Kato Y, Kiuchi Y. Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38. ***Cancer Chemother Pharmacol*** 83(5): 993-998, 2019.
DOI: 10.1007/s00280-019-03784-8

168) Al-Shammari AH, Masuo Y, Fujita K, Yoshikawa Y, Nakamichi N, Kubota Y, Sasaki Y, Kato Y*. Influx and efflux transporters contribute to the increased dermal exposure to active metabolite of regorafenib after repeated oral administration. ***J Pharm Sci*** 108(6): 2173-2179, 2019.
DOI: 10.1016/j.xphs.2019.01.018

167) Nakamichi N, Nakao S, Masuo Y, Koike A, Matsumura N, Nishiyama M, Al-Shammari AH, Sekiguchi H, Sutoh K, Usumi K, Kato Y*. Hydrolyzed salmon milt extract enhances object recognition and location memory through an increase in hippocampal cytidine nucleoside levels in

normal mice. ***J Med Food*** 22(4): 408-415, 2019.

166) Ishimoto T, Masuo Y, Kato Y, and Nakamichi N. Ergothioneine-induced neuronal differentiation is mediated through activation of S6K1 and neurotrophin 4/5-TrkB signaling in murine neural stem cells. ***Cell Signal*** 53: 269-280, 2019.
DOI: 10.1016/j.cellsig.2018.10.012

165) Hashimoto S, Honda K, Fujita K, Miyachi Y, Isoda K, Misaka K, Suga Y, Kato S, Tsuchiya H, Kato Y, Okajima M, Taniguchi T, Shimada T, Sai Y. Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies. ***J Pharm Health Care Sci*** 4: 27, 2018.
DOI: 10.1186/s40780-018-0123-1

164) Tashiro Y, Sakai R, Hirose-Sugiura T, Kato Y, Matsuo H, Takada T, Suzuki H, Makino T. Effects of osthol isolated from cnidium monnieri fruit on urate transporter. ***Molecules*** 23(11), 2018.
DOI: 10.3390/molecules23112837

163) Masuo Y, Ohba Y, Yamada K, Al-Shammari AH, Seba N, Nakamichi N, Ogihara T, Kunishima M, Kato Y*. Combination metabolomics approach for identifying endogenous substrates of carnitine/organic cation transporter OCTN1. ***Pharm Res*** 35(11): 224, 2018.
DOI: 10.1007/s11095-018-2507-1

162) Futatsugi A, Toshimoto K, Yoshikado T, Sugiyama Y, Kato Y*. Evaluation of alteration in hepatic and intestinal BCRP function in vivo due to ABCG2 c.421C>A polymorphism based on PBPK analysis of rosuvastatin. ***Drug Metab Dispos*** 46(5): 749-757, 2018.
DOI: 10.1124/dmd.117.078816

161) Ellawatty WEA, Masuo Y, Fujita K, Yamazaki E, Ishida H, Arakawa H, Nakamichi N, Abdelwahed R, Sasaki Y, Kato Y* . Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib. ***Drug Metab Dispos*** 46(1): 33-40, 2018.
DOI: 10.1124/dmd.117.076554

160) Ishimoto T, Nakamichi N, Nishijima H, Masuo Y, Kato Y. Carnitine/organic cation transporter OCTN1 negatively regulates activation in murine cultured microglial cells. ***Neurochem Res*** 43(1): 107-119, 2018.
DOI: 10.1007/s11064-017-2350-5

159) Arakawa H, Washio I, Matsuoka N, Kubo H, Staub AY, Nakamichi N, Ishiguro N, Kato Y, Nakanishi T, Tamai I. Usefulness of kidney slices for functional analysis of apical reabsorptive transporters. ***Sci Rep*** 7(1):12814, 2017.
DOI: 10.1038/s41598-017-12828-z

158) Shinozaki Y, Furuichi K, Toyama T, Kitajima S, Hara A, Iwata Y, Sakai N, Shimizu M, Kaneko S, Isozumi N, Nagamori S, Kanai Y, Sugiura T, Kato Y, Wada T. Impairment of the carnitine/organic cation transporter 1-ergothioneine axis is mediated by intestinal transporter dysfunction in chronic kidney disease. ***Kid Int*** 92(6): 1356-1369, 2017.
DOI: 10.1016/j.kint.2017.04.032

157) Fujita K, Masuo Y, Yamazaki E, Shibutani T, Kubota Y, Nakamichi N, Sasaki Y, Kato Y*. Involvement of the transporters P-glycoprotein and breast cancer resistance protein in dermal distribution of the multikinase inhibitor regorafenib and its active metabolites. ***J Pharm Sci*** 106(9): 2632-2641, 2017.
DOI: 10.1016/j.xphs.2017.04.064

156) Masuo Y, Nagamori S, Hasegawa A, Hayashi K, Isozumi N, Nakamichi N, Kanai Y, Kato Y*. Utilization of liver microsomes to estimate hepatic intrinsic clearance of monoamine oxidase substrate drugs in humans. ***Pharm Res*** 34(6): 1233-1243, 2017.
DOI: 10.1007/s11095-017-2140-4

155) Hashimoto N, Nakamichi N, Yamazaki E, Oikawa M, Masuo Y, Schinkel AH, Kato Y*. P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids. ***Int J Pharm*** 521(1-2): 365-373, 2017.
DOI: 10.1016/j.ijpharm.2017.02.064

154) Abouzed TK, Munesue S, Harashima A, Masuo Y, Kato Y, Kahilo KKK, Yamamoto H, Yamamoto Y. Preventive effect of salicylate and pyridoxamine on diabetic nephropathy. ***J Diabetes Res*** 2016: 1786789, 2016.
DOI: 10.1155/2016/1786789

153) Nakamichi N, Ishimoto T, Yamauchi Y, Masuo Y, Kato Y*. Screening to identify multidrug

resistance-associated protein inhibitors with neuroblastoma-selective cytotoxicity. ***Biol Pharm Bull*** 39(10):1638-1645, 2016.
DOI: 10.1248/bpb.b16-00319

152) Futatsugi A, Masuo Y, Kawabata S, Nakamichi N, Kato Y*. L503F variant of carnitine/organic cation transporter 1 efficiently transports metformin and other biguanides. ***J Pharm Pharmacol*** 68(9): 1160-1169, 2016.
DOI: 10.1111/jphp.12574

151) Taguchi T, Masuo Y, Kogi T, Nakamichi N, Kato Y*. Characterization of long-lasting Oatp inhibition by typical inhibitor cyclosporine A and in vitro-in vivo discrepancy in its drug interaction potential in rats. ***J Pharm Sci*** 105(7): 2231-2239, 2016.
DOI: 10.1016/j.xphs.2016.04.025

150) Nakamichi N, Nakayama K, Ishimoto T, Masuo Y, Wakayama T, Sekiguchi H, Sutoh K, Usumi K, Iseki S, Kato Y*. Food-derived hydrophilic antioxidant ergothioneine is distributed to the brain and exerts antidepressant effect in mice. ***Brain Behav*** 6(6): e00477, 2016.
DOI: 10.1002/brb3.477

149) Ben Said M, Grati M, Ishimoto T, Zou B, Chakchouk I, Ma Q, Yao Q, Hammami B, Yan D, Mittal R, Nakamichi N, Ghorbel A, Neng L, Tekin M, Shi XR, Kato Y, Masmoudi S, Lu Z, Hmani M, Liu X. A mutation in SLC22A4 encoding an organic cation transporter expressed in the cochlea strial endothelium causes human recessive non-syndromic hearing loss DFNB60. ***Human Genetics*** 135(5): 513-524, 2016.
DOI: 10.1007/s00439-016-1657-7

148) Wei L, Tominaga H, Ohgaki R, Wiriyasermkul P, Hagiwara K, Okuda S, Kaira K, Kato Y, Oriuchi N, Nagamori S, Kanai Y. Transport of 3-fluoro-L-α-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [^{18}F]FAMT positron emission tomography. ***J Pharmacol Sci*** 130(2): 101-109, 2016.
DOI: 10.1016/j.jphs.2016.01.001

147) Tang Y, Masuo Y, Sakai Y, Wakayama T, Sugiura T, Harada R, Futatsugi A, Komura T, Nakamichi N, Sekiguchi H, Sutoh K, Usumi K, Iseki S, Kaneko S, Kato Y*. Localizatoin of xenobiotic transporter OCTN1/SLC22A4 in hepatic stellate cells and its protective role in liver fibrosis. ***J Pharm Sci*** 105(5): 1779-1789, 2016.
DOI: 10.1016/j.xphs.2016.02.023

146) Yamada T, Takakura H, Jue T, Hashimoto T, Ishizawa R, Furuichi Y, Kato Y, Iwanaka N, Masuda K. Myoglobin and the regulation of mitochondrial respiratory chain complex IV. ***J Physiol*** 594(2): 483-495, 2016.
DOI: 10.1113/JP270824

145) Fujita K, Masuo Y, Okumura H, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Akiyama Y, Kitamura M, Kunishima M, Sasaki Y, Kato Y*. Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure. ***Pharm Res*** 33(2): 269-282, 2016.
DOI: 10.1007/s11095-015-1785-0

144) Naka K, Jomen Y, Ishihara K, Kim J, Ishimoto T, Bae E, Mohney R, Stirdivant SM, Oshima H, Oshima M, Kim DW, Nakauchi H, Takihara Y, Kato Y, Ooshima A, Kim SJ. Dipeptide species regulate nutrient signalling essential for the maintenance of chronic myelogenous leukaemia stem cells. ***Nat Commun*** 6: 8039, 2015.
doi: 10.1038/ncomms9039

143) Shimizu T, Kijima A, Masuo Y, Ishimoto T, Sugiura T, Takahashi S, Nakamichi N, Kato Y*. Gene ablation of carnitine/organic cation transporter 1 reduces gastrointestinal absorption of 5-aminosalicylate in mice. ***Biol Pharm Bull*** 38(5): 774-780, 2015 (Highlighted paper selected by Editor-in-Chief).
DOI: 10.1248/bpb.b15-00109

142) Shimizu T, Masuo Y, Takahashi S, Nakamichi N, Kato Y*. Organic cation transporter Octn1-mediated uptake of food-derived antioxidant ergothioneine into infiltrating macrophages during intestinal inflammation in mice. ***Drug Metab Pharmacokinet*** 30(3): 231-239, 2015.
DOI: 10.1016/j.dmpk.2015.02.003

141) Matsuo H, Yamamoto K, Nakaoka H, Nakayama A, Sakiyama M, Chiba T, Takahashi A,

Nakamura T, Nakashima H, Takada Y, Danjoh I, Shimizu S, Abe J, Kawamura Y, Terashige S, Ogata H, Tatsukawa S, Yin G, Okada R, Morita E, Naito M, Tokumasu A, Onoue H, Iwaya K, Ito T, Takada T, Inoue K, Kato Y, Nakamura Y, Sakurai Y, Suzuki H, Kanai Y, Hosoya T, Hamajima N, Inoue I, Kubo M, Ichida K, Ooyama H, Shimizu T, Shinomiya N. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. ***Ann Rheum Dis*** 75(4): 652-659, 2016.
DOI: 10.1136/annrheumdis-2014-206191

140) Kawase A, Sakata M, Yada N, Nakasaka M, Shimizu T, Kato Y, Iwaki M. Decreased radixin function for ABC transporters in liver in adjuvant-induced arthritis rats. ***J Pharm Sci*** 103(12): 4058-4065, 2014.
DOI: 10.1002/jps.24210

139) Kawase A, Norikane S, Okada A, Adachi M, Kato Y, Iwaki M. Distinct alterations in ABC transporter expression in liver, kidney, small intestine, and brain in adjuvant-induced arthritic rats. ***J Pharm Sci*** 103(8): 2556-2564, 2014.
DOI: 10.1002/jps.24043

138) Adachi E, Hirose-Sugiura T, Kato Y, Ikebuchi F, Yamashita A, Abe T, Fukuta K, Adachi K, Matsumoto K. Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury. ***Pharmacology*** 94(3-4): 190-187, 2014.

137) Ishimoto T, Nakamichi N, Hosotani H, Masuo Y, Sugiura T, Kato Y*. Organic cation transporter-mediated ergothioneine uptake in mouse neural progenitor cells suppresses proliferation and promotes differentiation into neurons. ***PLoS One*** 9(2): e89434, 2014.

136) Takeuchi K, Sugiura T, Matsubara K, Sato R, Shimizu T, Masuo Y, Horikawa M, Nakamichi N, Ishiwata N, Kato Y*. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in human. ***Drug Metab Dispos*** 42(4): 726-734, 2014.

135) Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Sasaki Y, Kato Y*. Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. ***Pharm Res*** 31(1):204-215, 2014.

134) Nakayama A, Matsuo H, Shimizu T, Ogata H, Takada Y, Nakashima H, Nakamura T, Shimizu S, Chiba T, Sakiyama M, Ushiyama C, Takada T, Inoue K, Kawai S, Hishida A, Wakai K, Hamajima N, Ichida K, Sakurai Y, Kato Y, Shimizu T, Shinomiya N. A common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility. ***Hum Cell*** 26(4): 133-136, 2013.

133) Nakamichi N, Shima H, Asano S, Ishimoto T, Sugiura T, Matsubara K, Kusuhara H, Sugiyama Y, Sai Y, Miyamoto KI, Tsuji A, Kato Y*. Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin. ***J Pharm Sci*** 102(9): 3407-3417, 2013.

132) Yano K, Tomono T, Sakai R, Kano T, Morimoto K, Kato Y, Ogihara T. Contribution of radixin to P-glycoprotein expression and transport activity in mouse small intestine in vivo. ***J Pharm Sci*** 102(8): 2875-2881, 2013.

131) Liu H-X, Lopatina O, Higashida C, Fujimoto H, Akther S, Inzhutova A, Liang M, Zhong J, Tsuji T, Yoshihara T, Sumi K, Ishiyama M, Ma W-J, Ozaki M, Yagitani S, Yokoyama S, Mukaida N, Sakurai T, Hori O, Yoshioka K, Hirao A, Kato Y, Ishihara K, Kato I, Okamoto H, Cherepanov SM, Salmina A, Hirai H, Asano M, Brown DA, Nagano I, Higashida H. Displays of mouse pup retrieval as paternal parental behaviour following communicative interaction with maternal mates. ***Nat Commun*** 4: 1346, 2013.

130) Shitara Y, Nakamichi N, Norioka M, Shima H, Kato Y, Horie T. Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria. ***Toxicol Sci*** 132(1): 32-42, 2013.

129) Hashimoto N, Nakamichi N, Uwafuji S, Yoshida K, Sugiura T, Tsuji A, Kato Y*. ATP binding cassette transporters in two distinct compartments of skin contribute to transdermal absorption of a typical substrate. ***J Controlled Rel*** 165(1): 54-61, 2013.

128) Sugiura T, Takahashi S, Sano K, Abe T, Fukuta K, Adachi K, Nakamura T, Matsumoto K, Nakamichi N, Kato Y*. Pharmacokinetic modeling of hepatocyte growth factor in experimental

animals and humans. ***J Pharm Sci*** 102(1): 237-249, 2013.
127) Nakamichi N, Taguchi T, Hosotani H, Wakayama T, Shimizu T, Sugiura T, Iseki S, Kato Y*. Functional expression of carnitine/organic cation transporter OCTN1 in mouse brain neurons: Possible involvement in neuronal differentiation. ***Neurochem Int*** 61(7): 1121-1132, 2012.
126) Furuichi Y, Sugiura T, Kato Y, Takakura H, Hanai Y, Hashimoto T, Masuda K. Muscle contraction increases carnitine uptake via translocation of OCTN2. ***Biochem Biophys Res Commun*** 418(4): 774-779, 2012.
125) Shimizu T, Sugiura T, Wakayama T, Kijima A, Nakamichi N, Iseki S, Silver DL, Kato Y*. PDZK1 regulates breast cancer resistance protein in small intestine. ***Drug Metab Dispos*** 39(11): 2148-2154, 2011.
124) Kano T, Wada S, Morimoto K, Kato Y, Ogihara T. Effect of knockdown of ezrin, radixin and moesin on P-glycoprotein function in HepG2 cells. ***J Pharm Sci*** 100(12): 5308-5314, 2011.
123) Takeuchi K, Sugiura T, Umeda S, Matsubara K, Horikawa M, Nakamichi N, Silver DL, Ishiwata N, Kato Y*. Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-Increasing agent. ***Drug Metab Dispos*** 39(6): 1088-1096, 2011.
122) Sugiura T, Otake T, Shimizu T, Wakayama T, Silver DL, Utsumi R, Nishimura T, Iseki S, Nakamichi N, Kubo Y, Tsuji A, Kato Y*. PDZK1 regulates organic anion transporting polypeptide Oatp1a in mouse small intestine. ***Drug Metab Pharmacokinet*** 25(5): 588-598, 2010.
121) Meng Q, Liu Q, Wang C, Sun H, Kaku T, Kato Y, Liu K. Molecular mechanisms of biliary excretion of cefditoren and the effects of cefditoren on the expression levels of hepatic transporters. ***Drug Metab Pharmacokinet*** 25(4): 320–327, 2010.
120) Sugiura T, Kato S, Shimizu T, Wakayama T, Nakamichi N, Kubo Y, Iwata D, Suzuki K, Soga T, Asano M, Iseki S, Tamai I, Tsuji A, Kato Y*. Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver. ***Drug Metab Dispos*** 38(10): 1665-1672, 2010.
119) Furuichi Y, Sugiura T, Kato Y, Shimada Y, Masuda K. OCTN2 is associated with carnitine transport capacity of rat skeletal muscles. ***Acta Physiologica*** 200(1): 57-64, 2010.
118) Mitsuoka K, Kato Y, Miyoshi S, Murakami Y, Hiraiwa M, Kubo Y, Nishimura S, Tsuji A. Inhibition of oligopeptide transporter suppress growth of human pancreatic cancer cells. ***Eur J Pharm Sci*** 40(3): 202-208, 2010.
117) Kato Y, Kubo Y, Iwata D, Kato S, Sudo T, Sugiura T, Kagaya T, Wakayama T, Hirayama A, Sugimoto M, Sugihara K, Kaneko S, Soga T, Asano M, Tomita M, Matsui T, Wada M, Tsuji A. Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1. ***Pharm Res*** 27(5): 832-840, 2010.
116) Kato S, Kato Y, Nakamura T, Sugiura T, Kubo Y, Deguchi Y, Tsuji A. Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. ***Biopharm Drug Dispos*** 30(9): 495-507, 2009.
115) Mitsuoka K, Tamai I, Morohashi Y, Kubo Y, Saitoh R, Tsuji A, Kato Y*. Direct evidence for efficient transport and minimal metabolism of l-Cephalexin by PEPT1 in budded baculovirus fraction. ***Biol Pharm Bull*** 32(8): 1459-1461, 2009.
114) Kato S, Ito K, Kato Y, Wakayama T, Kubo Y, Iseki S, Tsuji1 A. Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate. ***Pharm Res*** 26(6): 1467-1476, 2009.
113) Kano T, Kato Y, Ito K, Ogihara T, Kubo Y, Tsuji A. Carnitine/organic cation transporter OCTN2 (Slc22a5) is responsible for renal secretion of cephaloridine in mice. ***Drug Metab Dispos*** 37(5): 1009-1016, 2009.
112) Liu KX, Kato Y, Matsumoto K, Nakamura T, Kaku T, Sugiyama Y. Characterization of the enhancing effect of protamine on the proliferative activity of hepatocyte growth factor in rat hepatocytes. ***Pharm Res*** 26(4): 1012-1021, 2009.
111) Kato Y, Sugiura T, Nakadera Y, Sugiura M, Kubo Y, Sato T, Harada A, Tsuji A. Investigation of the role of oligopeptide transporter PEPT1 and sodium/glucose cotransporter SGLT1 in intestinal absorption of their substrates using small GTP-binding protein Rab8 null mice. ***Drug Metab Dispos*** 37(3): 602-607, 2009.
110) Kato Y, Miyazaki T, Kano T, Sugiura T, Kubo Y, Tsuji A. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. ***J Pharm Sci*** 98(7): 2529-2539, 2009.

109) Ito K, Nguyen H-T, Kato Y, Wakayama T, Kubo Y, Iseki S, Tuji A. P-Glycoprotein (Abcb1) is involved in absorptive drug transport in skin. ***J Controlled Rel*** 131(3): 198-204, 2008.

108) Nakamura K, Ito K, Kato Y, Sugaya T, Kubo Y, Tsuji A. L-type fatty acid binding protein transgenic mouse as a novel tool to explore cytotoxicity to renal proximal tubules. ***Drug Metab Pharmacokinet*** 23(4): 271-278 2008.

107) Nishimura T, Kato Y, Amano N, Ono M, Kubo Y, Kimura Y, Fujita H, Tsuji A. Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat. ***Pharm Res*** 25(11): 2467-2476, 2008.

106) Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, Tsuji A. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of ß-lactam antibiotics. ***Drug Metab Dispos*** 36(6): 1088-1096, 2008.

105) Iwata D, Kato Y, Wakayama T, Sai Y, Kubo Y, Iseki S, Tsuji A. Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. ***Drug Metab Pharmacokin*** 23(3): 207-215, 2008.

104) Sugiura T, Kato Y, Wakayama T, Silver DL, Kubo Y, Iseki S, Tsuji A. PDZK1 regulates two intestinal solute carriers (Slc15a1 and Slc22a5) in mice. ***Drug Metab Dispos*** 36(6): 1181-1188, 2008.

103) Utsunomiya H, Katoono R, Yui N, Sugiura T, Kubo Y, Kato Y, Tsuji A. Cationic polyrotaxanes effectively inhibit uptake via carnitine/organic cationic transporter without cytotoxicity. ***Macromol Biosci*** 8(7): 665-669, 2008.

102) Mitsuoka K, Miyoshi S, Kato Y, Murakami Y, Utsumi R, Kubo Y, Hiraiwa M, Noda A, Nakamura Y, Nishimura S, Tsuji A. Cancer detection using a PET tracer, ^{11}C-glycylsarcosine, targeted to H^+/peptide transporter. ***J Nucl Med*** 49(4): 615-622, 2008 and **Cover Caption of Vol. 49(4), 2008**.

101) Sato T, Mushiake S, Kato Y, Sato K, Sato M, Takeda N, Ozono K, Miki K, Kubo Y, Tsuji A, Harada R, Harada A. The Rab8 GTPase regulates apical protein localization in intestinal cells. ***Nature*** 448(7151): 366-369, 2007.

100) Nishimura T, Amano N, Kubo Y, Ono M, Kato Y, Fujita H, Kimura Y, Tsuji A. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. ***Drug Metab Dispos*** 35(8): 1275-1284, 2007.

99) Ito K, Kato Y, Tsuji H, Nguyen HT, Kubo Y, Tsuji A. Involvement of organic anion transport system in transdermal absorption of flurbiprofen. ***J Controlled Rel*** 124(1-2): 60-68, 2007.

98) Yagi Y, Aoki M, Iguchi M, Shibasaki S, Kurosawa T, Kato Y, Tsuji A. Transporter-mediated hepatic uptake of ulifloxacin, an active metabolite of a prodrug-type new quinolone antibiotic prulifloxacin in rats. ***Drug Metab Pharmacokinet*** 22(5): 350-357, 2007.

97) Mitsuoka K, Kato Y, Kubo Y, Tsuji A. Functional expression of stereoselective metabolism of cephalexin by exogenous transfection of oligopeptide transporter PEPT1. ***Drug Metab Dispos*** 35(3): 356-362, 2007.

96) Nishimura T, Kubo Y, Kato Y, Sai Y, Ogihara T, Tsuji A. Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: Involvement of organic anion transporting polypeptide (OATP)-B. ***Pharm Res*** 24(1): 90-98, 2007.

95) Komoriya K, Kato Y, Hayashi Y, Ohsuye K, Nishigaki R, Sugiyama Y. Characterization of the hepatic disposition of lanoteplase, a rationally designed variant of tissue plasminogen activator in rodents. ***Drug Metab Dispos*** 35(3): 469-475, 2007.

94) Wakayama T, Sai Y, Ito A, Kato Y, Kurobo M, Murakami Y, Nakashima E, Tsuji A, Kitamura Y, Iseki S. Heterophilic binding of the adhesion molecules poliovirus receptor and immunoglobulin superfamily 4A in the interaction between mouse spermatogenic and Sertoli cells. ***Biol Reprod*** 76(6): 1081-1090, 2007.

93) Kato Y, Sugiura M, Sugiura T, Wakayama T, Kubo Y, Kobayashi D, Sai Y, Tamai I, Iseki S, Tsuji A. Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse. ***Mol Pharmacol*** 70(3): 829-837, 2006.

92) Watanabe C, Kato Y, Sugiura T, Kubo Y, Wakayama T, Iseki S, Tsuji A. PDZ adaptor protein PDZK2 stimulates transport activity of organic cation/carnitine transporter OCTN2 by modulating cell-surface expression. ***Drug Metab Dispos*** 34(11): 1927-1934, 2006 and **Cover Caption of Vol. 34(11), 2006**.

91) Sugiura T, Kato Y, Kubo Y, Tsuji A. Mutation in an adaptor protein PDZK1 affects transport activity of organic cation transporter OCTNs and oligopeptide transporter PEPT2. ***Drug Metab***

Pharmacokinet 21(5): 375-383, 2006.

90) Li Q, Tsuji H, Kato Y, Sai Y, Kubo Y, Tsuji A. Characterization of the transdermal transport of flurbiprofen and indomethacin. ***J Control Rel*** 110(3): 542-556, 2006.
89) Sai Y, Kato Y, Nakamura K, Kato S, Nishimura T, Kubo Y, Tamai I, Yang S, Hu Z, Yamada I, Tsuji A. Carrier-mediated hepatic uptake of a novel non-renal excretion type uric acid generation inhibitor, Y-700. ***J Pharm Sci*** 95(2): 336-347, 2006.
88) Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. ***Drug Metab Dispos*** 34(8): 1423-1431, 2006 and **Cover Caption of Vol. 34(8), 2006**.
87) Jin M, Shimada T, Yokogawa K, Nomura M, Kato Y, Tsuji A, Miyamoto K. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. ***Int J Pharm*** 309(1-2): 81-86, 2006.
86) Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, Kato Y, Tsuji A, Miyamoto K. Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. ***Biochem Pharmacol*** 72(8):1042-1050, 2006.
85) Wakayama T, Kato Y, Utsumi R, Tsuji A, Iseki S. A time- and cost-saving method of producing rat polyclonal antibodies. ***Acta Histochem Cytochem*** 39(3): 79-87, 2006.
84) Watanabe C, Kato Y, Ito S, Kubo Y, Sai Y, Tsuji A. Na^+/ H^+ exchanger 3 affects transport property of H^+/oligopeptide transporter 1. *Drug Metab Pharmacokinet.* **20**(6): 443-451, 2005.
83) Kato Y, Sai Y, Yoshida K, Watanabe C, Hirata T, Tsuji A. PDZK1 directly regulates the function of organic cation/carnitine transporter OCTN2. ***Mol Pharmacol*** 67(3): 734-743, 2005.
82) Li Q, Kato Y, Sai Y, Imai T, Tsuji A. Multidrug resistance-associated protein 1 functions as an efflux pump of xenobiotics in the skin. ***Pharm Res*** 22(6): 842-846, 2005.
81) Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. Carrier-mediated uptake of grepafloxacin, a fluoroquinolone antibiotic, by the isolated rat lung cells. ***Drug Metab Pharmacokinet*** 20(6): 491-495, 2005.
80) Kato Y, Yoshida K, Watanabe C, Sai Y, Tsuji A. Screening of the interaction between xenobiotic transporters and PDZ proteins. ***Pharm Res*** 21(10): 1886-1894, 2004.
79) Kawasaki Y, Kato Y, Sai Y, Tsuji A. Functional characterization of human organic cation transporter OCTN1 single nucleotide polymorphisms in the Japanese population. ***J Pharm Sci*** 93(12): 2920-2926, 2004.
78) Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. Differential involvement of multidrug resistance-associated protein 1 and p-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. ***J Pharmacol Exp Ther*** 310(2): 648-655, 2004.
77) Nishimura T, Kato Y, Sai Y, Ogihara T, Tsuji A. Characterization of renal excretion mechanism for a novel diuretic, M17055, in rats. ***J Pharm Sci*** 93(10): 2558-2566, 2004.
76) Inano A, Sai Y, Kato Y, Tamai I, Ishiguro M, Tsuji A. Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition. ***Drug Metab Pharmacokinet*** 19(3): 180-189, 2004.
75) Li Q, Sai Y, Kato Y, Muraoka H, Tamai I, Tsuji A. Transporter-mediated renal handling of nafamostat mesilate. ***J Pharm Sci*** 93(2): 262-272, 2004.
74) Yagi Y, Shibutani S, Hodoshima N, Ishiwata K, Okudaira N, Li Q, Sai Y, Kato Y, Tsuji A. Involvement of multiple transport systems in the disposition of an active metabolite of a prodrug-type new quinolone antibiotic, prulifloxacin. ***Drug Metab Pharmacokinet*** 18(6): 381-389, 2003.
73) Li Q, Sai Y, Kato Y, Tamai I, Tsuji A. Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines. ***Pharm Res*** 20(8): 1119-1124, 2003.
72) Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. ***Mol Pharmacol*** 63(4): 844-848, 2003.
71) Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, Sugiyama Y. Function of uptake transporters for taurocholate and estradiol 17beta-d-glucuronide in cryopreserved human hepatocytes. ***Drug Metab Pharmacokinet*** 18(1): 33-41, 2003.
70) Horikawa M, Kato Y, Tyson CA, Sugiyama Y. Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. ***Drug Metab Pharmacokinet*** 18(1): 16-22, 2003.

69) Janvier K, Kato Y, Boehm M, Rose JR, Martina JA, Kim BY, Venkatesan S, Bonifacino JS. Recognition of dileucine-based sorting signals from HIV-1 Nef and LIMP-II by the AP-1 gamma-sigma1 and AP-3 delta-sigma3 hemicomplexes. ***J Cell Biol*** 163(6): 1281-1290, 2003.
68) Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. ***Cancer Res*** 63(24): 8977-8983, 2003.
67) Suzuki T, Kato Y, Sasabe H, Itose M, Miyamoto G, Sugiyama Y. Mechanism for the tissue distribution of grepafloxacin, a fluoroquinolone antibiotic, in rats. ***Drug Metab Dispos*** 30(12): 1393-1399, 2002.
66) Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. ***J Pharmacol Exp Ther*** 302(2): 510-515, 2002.
65) Kato Y, Kuge K, Kusuhara H, Meier PJ, Sugiyama Y. Gender difference in the urinary excretion of organic anions in rats. ***J Pharmacol Exp Ther*** 302(2): 483-489, 2002.
64) Gotoh Y, Kato Y, Stieger B, Meier PJ, Sugiyama Y. Gender difference in the Oatp1-mediated tubular reabsorption of estradiol 17beta-D-glucuronide in rats. ***Am J Physiol*** 282(6): E1245-E1254, 2002.
63) Horikawa M, Kato Y, Sugiyama Y. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. ***Pharm Res*** 19(9): 1345-1353, 2002.
62) Horikawa M, Kato Y, Tyson CA, Sugiyama Y. The Potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. ***Drug Metab Pharmacokinet*** 17(1): 23-33, 2002.
61) Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. ***Pharm Res*** 19(2): 147-153, 2002.
60) Maeda K, Kato Y, Sugiyama Y. pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes. ***J Control Rel*** 82(1): 71-82, 2002.
59) Sato H, Kato Y, Hayasi E, Tabata T, Suzuki M, Takahara Y, Sugiyama Y. A novel hepatic-targeting system for therapeutic cytokines that delivers to the hepatic asialoglycoprotein receptor, but avoids receptor-mediated endocytosis. ***Pharm Res*** 19(11): 1736-1744, 2002.
58) Kato Y, Misra S, Puertollano R, Hurley JH, Bonifacino JS. Phosphoregulation of sorting signal-VHS domain interactions by a direct electrostatic mechanism. ***Nat Struct Biol*** 9(7): 532-536, 2002.
57) Misra S, Puertollano R, Kato Y, Bonifacino JS, Hurley JH. Structural basis for acidic-cluster-dileucine sorting-signal recognition by VHS domains. ***Nature*** 415(6874): 933-937, 2002.
56) Ueda K, Kato Y, Komatsu K, Sugiyama Y. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. ***J Pharmacol Exp Ther*** 297(3): 1036-1043, 2001.
55) Han YH, Kato Y, Watanabe Y, Terao K, Asoh Y, Sugiyama Y. Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-dianninopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats. ***Drug Metab Dispos*** 29(4 Pt 1): 394-400, 2001.
54) Han YH, Kato Y, Haramura M, Ohta M, Matsuoka H, Sugiyama Y. Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2). ***Pharm Res*** 18(5): 579-586, 2001.
53) Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. ***Pharm Res*** 18(8): 1190-1202, 2001.
52) Tsukamoto Y, Kato Y, Ura M, Horii I, Ishikawa T, Ishitsuka H, Sugiyama Y. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model. ***Biopharm Drug Dispos*** 22(1): 1-14, 2001.
51) Shirota K, Kato Y, Suzuki K, Sugiyama Y. Characterization of novel kidney-specific delivery system using an alkylglucoside vector. ***J Pharmacol Exp Ther*** 299(2): 459-467, 2001.

50) Mizuno N, Kato Y, Iwamoto M, Urae A, Amamoto T, Niwa T, Sugiyama Y. Kinetic analysis of the disposition of insulin-like growth factor 1 in healthy volunteers. ***Pharm Res*** 18(8):1203-1209, 2001.
49) Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. ***J Control Rel*** 77(1-2): 27-38, 2001.
48) Nishiyama N, Kato Y, Sugiyama Y, Kataoka K. Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. ***Pharm Res*** 18(7): 1035-1041, 2001.
47) Shirota K, Kato Y, Irimura T, Kondo H, Sugiyama Y. Anti-metastatic effect of the sialyl Lewis-X analog GSC-150 on the human colon carcinoma derived cell line KM12-HX in the mouse. ***Biol Pharm Bull*** 24(3): 316-319, 2001.
46) Nishino A, Kato Y, Igarashi T, Sugiyama Y. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan. ***Drug Metab Dispos*** 28(10): 1146-1148, 2000.
45) Liu KX, Kato Y, Kaku TI, Santa T, Imai K, Yagi A, Ishizu T, Sugiyama Y. Hydroxyprolylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats. ***J Pharmacol Exp Ther*** 294(2): 510-515, 2000.
44) Han YH, Kato Y, Sugiyama Y. Binding and transport of methotrexate and its derivative, MX-68, across the brush-border membrane in rat kidney. ***Biopharm Drug Dispos*** 20(8): 361-367, 1999.
43) Gotoh Y, Suzuki H, Kinoshita S, Hirohashi T, Kato Y, Sugiyama Y. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance- associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. ***J Pharmacol Exp Ther*** 292(1): 433-439, 2000.
42) Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy ipentanamide and p-glycoprotein by valspodar in gene transfectant systems. ***Drug Metab Dispos*** 28(10): 1238-1243, 2000.
41) Chu XY, Kato Y, Sugiyama Y. Possible involvement of p-glycoprotein in biliary excretion of CPT-11 in rats. ***Drug Metab Dispos*** 27(4): 440-441, 1999.
40) Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S, Sugiyama Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. ***J Pharmacol Exp Ther*** 288(2): 735-741, 1999.
39) Han YH, Kato Y, Sugiyama Y. Nonlinear disposition kinetics of a novel antifolate, MX-68, in rats. ***J Pharmacol Exp Ther*** 291(1): 204-212, 1999.
38) Akhteruzzaman S, Kato Y, Kouzuki H, Suzuki H, Hisaka A, Stieger B, Meier PJ, Sugiyama Y. Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats. ***J Pharmacol Exp Ther*** 290(3): 1107-1115, 1999.
37) Kino I, Kato Y, Lin JH, Sugiyama Y. Renal handling of biphosphonate alendronate in rats. ***Biopharm Drug Dispos*** 20(4): 193-198, 1999.
36) Han YH, Kato Y, Kusuhara H, Suzuki H, Shimoda M, Kokue E, Sugiyama Y. Kinetic profile of overall elimination of 5-methyltetrahydropteroylglutamate in rats. ***Am J Physiol*** 276(3 Pt 1): E580-E587, 1999.
35) Sasabe H, Kato Y, Terasaki T, Tsuji A, Sugiyama Y. Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. ***Biopharm Drug Dispos*** 20(3): 151-158, 1999.
34) Niinuma K, Kato Y, Suzuki H, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, Sugiyama Y. Primary active transport of organic anions on bile canalicular membrane in humans. ***Am J Physiol*** 276(5 Pt 1): G1153-G1164, 1999.
33) Akhteruzzaman S, Kato Y, Hisaka A, Sugiyama Y. Primary active transport of peptidic endothelin antagonists by rat hepatic canalicular membrane. ***J Pharmacol Exp Ther*** 288(2): 575-581, 1999.
32) Kato Y, Akhteruzzaman S, Hisaka A, Sugiyama Y. Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats. ***J Pharmacol Exp Ther*** 288(2): 568-574, 1999.
31) Kato M, Kato Y, Sugiyama Y. Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen. ***Am J Physiol*** 276(5 Pt 1): E887-E895, 1999.
30) Kato M, Kato Y, Nakamura T, Sugiyama Y. Efficient extraction by the liver governs overall

elimination of hepatocyte growth factor in rats. ***J Pharmacol Exp Ther*** 290(1): 373-379, 1999.
29) Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, Sugiyama Y. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. ***Cancer Res*** 58(22): 5137-5143, 1998.
28) Sasabe H, Kato Y, Tsuji A, Sugiyama Y. Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. ***J Pharmacol Exp Ther*** 284(2): 661-668, 1998.
27) Yamada T, Kato Y, Kusuhara H, Lemaire M, Sugiyama Y. Characterization of the transport of a cationic octapeptide, octreotide, in rat bile canalicular membrane: possible involvement of P-glycoprotein. ***Biol Pharm Bull*** 21(8): 874-878, 1998.
26) Liu KX, Kato Y, Kino I, Nakamura T, Sugiyama Y. Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats. ***Am J Physiol*** 275(5 Pt 1): E835-E842, 1998.
25) Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Pharmacokinetics of erythropoietin in genetically anemic mice. ***Drug Metab Dispos*** 26(2): 126-131, 1998.
24) Shitara Y, Kato Y, Sugiyama Y. Effect of brefeldin A and lysosomotropic reagents on intracellular trafficking of epidermal growth factor and transferrin in Madin-Darby canine kidney epithelial cells. ***J Control Rel*** 55(1): 35-43, 1998.
23) Liu KX, Kato Y, Kaku TI, Matsumoto K, Nakamura T, Sugiyama Y. Protamine enhances the proliferative activity of hepatocyte growth factor in rats. ***Am J Physiol*** 274(1 Pt 1): G21-G28, 1998.
22) Mizuno N, Kato Y, Shirota K, Izumi Y, Irimura T, Harashima H, Kiwada H, Motoji N, Shigematsu A, Sugiyama Y. Mechanism of initial distribution of blood-borne colon carcinoma cells in the liver. ***J Hepatol*** 28(5): 878-885, 1998.
21) Mizuno N, Kato Y, Izumi Y, Irimura T, Sugiyama Y. Importance of hepatic first-pass removal in metastasis of colon carcinoma cells. ***J Hepatol*** 28(5): 865-877, 1998.
20) Liu KX, Kato Y, Kaku T, Sugiyama Y. Human placental extract stimulates liver regeneration in rats. ***Biol Pharm Bull*** 21(1): 44-49, 1998.
19) Niinuma K, Takenaka O, Horie T, Kobayashi K, Kato Y, Suzuki H, Sugiyama Y. Kinetic analysis of the primary active transport of conjugated metabolites across the bile canalicular membrane: comparative study of S-(2,4-dinitrophenyl)-glutathione and 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole glucuronide. ***J Pharmacol Exp Ther*** 282(2): 866-872, 1997.
18) Masuda M, I'izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni'inuma K, Suzuki H, Sugiyama Y. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. ***Cancer Res*** 57(16): 3506-3510, 1997.
17) Chu XY, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. ***Cancer Res*** 57(10): 1934-1938, 1997.
16) Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, Sugiyama Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. ***J Pharmacol Exp Ther*** 281(1): 304-314, 1997.
15) Shin HC, Kato Y, Yamada T, Niinuma K, Hisaka A, Sugiyama Y. Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123. ***Am J Physiol*** 272(5 Pt 1): G979-G986, 1997.
DOI: 10.1152/ajpgi.1997.272.5.G979
14) Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. ***J Pharmacol Exp Ther*** 283(2): 520-527, 1997.
13) Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics. ***Drug Metab Dispos*** 25(9): 1039-1044, 1997.
12) Liu KX, Kato Y, Kato M, Kaku TI, Nakamura T, Sugiyama Y. Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats. ***Am J Physiol*** 273(5 Pt 1): E891-E897, 1997.
DOI: 10.1152/ajpendo.1997.273.5.E891
11) Kozu A, Kato Y, Shitara Y, Hanano M, Sugiyama Y. Kinetic analysis of transcytosis of epidermal growth factor in Madin-Darby canine kidney epithelial cells. ***Pharm Res*** 14(9): 1228-1235, 1997.
DOI: 10.1023/a:1012167126364

10) Hamada T, Kato Y, Terasaki T, Sugiyama Y. Cell density-dependent mitogenic effect and -independent cellular handling of epidermal growth factor in primary cultured rat hepatocytes. ***J Hepatol*** 26(2): 353-360, 1997.
doi: 10.1016/s0168-8278(97)80052-9.

9) Shin HC, Kato Y, Shitara Y, Yamada T, Nakamura T, Hisaka A, Sugiyama Y. The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123. ***J Pharmacol Exp Ther*** 278(2): 607-613, 1996.
DOI: 10.1016/S0022-3565(25)20642-5

8) Liu KX, Kato Y, Terasaki T, Aoki S, Okumura K, Nakamura T, Sugiyama Y. Contribution of parenchymal and non-parenchymal liver cells to the clearance of hepatocyte growth factor from the circulation in rats. ***Pharm Res*** 12(11): 1737-1740, 1995.
DOI: 10.1023/a:1016273907749

7) Liu KX, Kato Y, Terasaki T, Nakamura T, Sugiyama Y. Change in hepatic handling of hepatocyte growth factor during liver regeneration in rats. ***Am J Physiol*** 269(5 Pt 1): G745-G753, 1995.
DOI: 10.1152/ajpgi.1995.269.5.G745

6) Kato Y, Liu KX, Nakamura T, Sugiyama Y. Heparin-hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity. ***Hepatology*** 20(2): 417-424, 1994.
DOI: 10.1002/hep.1840200223

5) Ichikawa M, Kato Y, Miyauchi S, Sawada Y, Iga T, Fuwa T, Hanano M, Sugiyama Y. Effect of perfusate pH on the influx of 5-5'-dimethyl-oxazolidine-2,4-dione and dissociation of epidermal growth factor from the cell-surface receptor: the existence of the proton diffusion barrier in the Disse space. ***J Hepatol*** 20(2): 190-200, 1994.
DOI: 10.1016/s0168-8278(05)80057-1

4) Liu KX, Kato Y, Yamazaki M, Higuchi O, Nakamura T, Sugiyama Y. Decrease in the hepatic clearance of hepatocyte growth factor in carbon tetrachloride-intoxicated rats. ***Hepatology*** 17(4): 651-660, 1993.
DOI: 10.1002/hep.1840170420

3) Kato Y, Sugiyama Y. Binding, internalization, degradation, and mitogenic effect of epidermal growth factor in cultured rat hepatocytes. ***STP Pharm Sci*** 3(1): 75-82, 1993.

2) Liu KX, Kato Y, Narukawa M, Kim DC, Hanano M, Higuchi O, Nakamura T, Sugiyama Y. Importance of the liver in plasma clearance of hepatocyte growth factors in rats. ***Am J Physiol*** 263(5 Pt 1): G642-G649, 1992.
DOI: 10.1152/ajpgi.1992.263.5.G642

1) Kato Y, Sato H, Ichikawa M, Suzuki H, Sawada Y, Hanano M, Fuwa T, Sugiyama Y. Existence of two pathways for the endocytosis of epidermal growth factor by rat liver: phenylarsine oxide-sensitive and -insensitive pathways. ***Proc Natl Acad Sci USA*** 89(18): 8507-8511, 1992.
DOI: 10.1073/pnas.89.18.8507

2-1. Review articles（*, corresponding author; †, peer reviewed）

R20†) Yoshihara M, Mizutani S, Matsumoto K, Kato Y, Masuo Y, Arita H, Iyoshi S, Tano S, Mizutani H, Kotani T, Mizutani E, Shibata K, Kajiyama H. The balance between fetal oxytocin and placental leucine aminopeptidase (P-LAP) controls human uterine contraction around labor onset. ***Eur J Obstet Gynecol Reprod Biol*** 19 (2023) 100210.

R19†) Arakawa H, Kato Y*. Emerging roles of uremic toxins and inflammatory cytokines in the alteration of hepatic drug disposition in patients with kidney dysfunction. ***Drug Metab Dispos*** 51(9): 1127-1135, 2023.

R18†) Yoshihara M, Mizutani S, Matsumoto K, Kato Y, Masuo Y, Tano S, Mizutani H, Kotani T, Mizutani E, Shibata K, Kajiyama H. Crosstalk between foetal vasoactive peptide hormones and placental aminopeptidases regulates placental blood flow: Its significance in preeclampsia. ***Placenta*** 121: 32-39, 2022.

R17†) Ishimoto T, Kato Y*. Ergothioneine in the brain. ***FEBS Lett*** 596(10):1290-1298, 2022.

*Top Cited Article 2022-2023 (one of the top 10 most-cited papers in FEBS letters among work published between 1st January 2022 – 31st December 2023).

*Top Downloaded Article (one of the most downloaded during its first 12 months of publication in

FEBS Letters among work published in an issue between 1 January 2022 – 31 December 2022)

R16†) Yoshihara M, Mizutani S, Kato Y, Matsumoto K, Mizutani E, Mizutani H, Fujimoto H, Otsuka S, Kajiyama H. Recent Insights into Human Endometrial Peptidases in Blastocyst Implantation via Shedding of Microvesicles. ***Int J Mol Sci*** 22(24): 13479, 2021.

R15†) Mizutani S, Matsumoto K, Kato Y, Mizutani E, Mizutani H, Iwase A, Shibata K. New insights into human endometrial aminopeptidases in both implantation and menstruation. ***Biochim Biophys Acta*** 1868(2): 140332, 2020.

R14†) Fujita K, Matsumoto N, Ishida H, Kubota Y, Iwai S, Shibanuma M, Kato Y. Decreased disposition of anticancer drugs predominantly eliminated via the liver in patients with renal failure. ***Curr Drug Metab*** 20(5): 361-376, 2019.

R13†) Nakamichi N, Kato Y. Physiological roles of carnitine/organic cation transporter OCTN1/SLC22A4 in neural cells. ***Biol Pharm Bull*** (review) 40(8): 1146-1152, 2017.

R12†) Ehrhardt C, Bäckman P, Couet W, Edwards C, Forbes B, Fridén M, Gumbleton M, Hosoya K, Kato Y, Nakanishi T, Takano M, Terasaki T, Yumoto R. Current progress toward a better understanding of drug disposition within the lungs: summary proceedings of the 1st Workshop on Drug Transporters in the Lungs. ***J Pharm Sci*** 106(9):2234-2244, 2017.

R11†) Erdő F, Karvaly G, Hashimoto N, Nakamichi N, Kato Y. Critical evaluation and methodological positioning of the transdermal microdialysis technique. A review. ***J Controlled Rel*** (review) 233: 147-161, 2016.

R10†) Sugiura T, Shimizu T, Kijima A, Minakata S, Kato Y*. PDZ adaptors: Their regulation of epithelial transporters and involvement in human diseases. ***J Pharm Sci*** 100(9):3620-3635, 2011.

R9†) Kato Y*. Xenobiotic transporter-adaptor network. ***Drug Metab Pharmacokin*** 22(6): 401-408, 2007.

R8†) Kato Y, Watanabe C, Tsuji A. Regulation of drug transporters by PDZ adaptor proteins and nuclear receptors. ***Eur J Pharm Sci*** (review) 27(5): 487-500, 2006.

R7†) Sugiura T, Kato Y, Tsuji A. Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition. ***J Controlled Rel*** (review) 116(2): 238-246, 2006.

R6) Kubo Y, Nakamura T, Iwata D, Kato Y, Tsuji A. Functional analysis of organic cation transporter OCTNs in mouse renal brush border membrane. ***Pharmazie*** 61(2): 171, 2006.

R5) Kato Y, Suzuki H, Sugiyama Y. Toxicological implications of hepatobiliary transporters. ***Toxicology*** (review) 181-182: 287-290, 2002.

R4) Sugiyama Y, Kato Y, Chu X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. ***Cancer Chemother Pharmacol*** 42 Suppl: S44-S49, 1998.

R3†) Kato Y, Sugiyama Y. Peptide and protein delivery targeted to receptor-mediated endocytosis. ***Crit Rev Ther Drug Carrier Systems*** 14(3): 173-219, 1997.

R2) Kato Y, Seita T, Kuwabara Y, Sugiyama Y. Kinetic analysis of receptor- mediated endocytosis (RME) of proteins and peptides: Use of RME as a drug delivery system. ***J Controlled Rel*** (review) 39: 191-200, 1996.

R1) Sugiyama Y, Kato Y. Pharmacokinetic aspects of peptide delivery and targeting: Importance of receptor-mediated endocytosis. ***Drug Dev Indust Pharmacy*** 20(4): 591-614, 1994.

2-2. Review articles 総説（和文）

RJ38)守友　輝、加藤　将夫
エルゴチオネインの生理作用
生物工学会誌 103(10): 480-483, 2025.

RJ37)加藤将夫、河西 巧、荒川 大
Organs-on-a-chip を利用した薬物動態における臓器間相互作用の理解
臨床薬理 Jpn J Clin Pharmacol 51(3): 174-176, 2020.

RJ36)石本尚大、加藤将夫
中枢神経系細胞に発現する薬物トランスポーターとその働き
医学のあゆみ 271(1): 33-41, 2019.

RJ35)島田和弘、加藤将夫
皮膚トランスポーターのホメオスタシス、薬物動態に及ぼす役割
Drug Delivery System 33(4): 259-267, 2018.
RJ34)荒川 大、加藤将夫
腎・肝障害患者における薬物動態変動：臓器内・臓器間連鎖の関与
医学のあゆみ 264(7): 584-589, 2018.
RJ33)橋本直人、中道範隆、加藤将夫
皮膚 ABC 膜輸送体に及ぼす外用添加物の影響
Fragrance Journal 7: 49-54, 2017.
RJ32)加藤将夫、三田村萌恵、松本　聡
トランスポーター介在性ブレインフードとしてのエルゴチオネイン
FOOD Style 21(2): 21-24, 2017.
RJ31)石本尚大、加藤将夫
薬物動態とは～薬物の生体内動態と薬物速度論～
Clinical Calcium 26(11)「骨粗鬆症治療薬の薬物動態と使用法～薬物の生体内動態と薬物速度論～」（ゲスト編集：三浦雅一）: 9-17, 2016.
RJ30)中道範隆、加藤将夫
神経細胞に発現する異物取り込みトランスポーターの役割
ファルマシア（最前線）51(4): 337-341, 2015.
RJ29)中道範隆、及川真志、加藤将夫
皮膚に発現するトランスポーターとその役割
コスメテックジャパン 4(2): 17-21, 2014.
RJ28)加藤将夫
トランスポーターと医薬品毒性の複雑な関係
谷本学校毒性質問箱 : 他では聞けない、くすり開発現場の基礎知識（サイエンティスト社）, **15** 号: 41-49, 2013.
RJ27) 清水卓也、加藤将夫
OCTN1(SLC22A4)と ergothioneine の生理的役割と疾患への関与
医薬のあゆみ, **245**(1): 36-42, 2013.
RJ26) 杉浦智子、加藤将夫
メタボロミクスによるトランスポーター機能の探索
細胞工学, 31(5) 新たな創薬ターゲットとしてのトランスポーター、金井好克監修
株式会社学研メディカル秀潤社、pp. 546-547 (2012 年 4 月)
RJ25)清水卓也、杉浦智子、加藤将夫
遺伝子欠損マウスのメタボローム解析による OCTN1 (SLC22A4)の生体内機能の解明
遺伝子医学 MOOK (19) トランスポートソーム-生体膜輸送機構の全体像に迫る、金井好克編
株式会社メディカルドゥ、pp. 77-82（2011 年 3 月）
RJ24)杉浦智子、加藤将夫
低分子量 GTP 結合タンパク質 Rab8 による SLC トランスポーターを介した消化管吸収制御
遺伝子医学 MOOK (19) トランスポートソーム-生体膜輸送機構の全体像に迫る、金井好克編
株式会社メディカルドゥ、pp. 265-270（2011 年 3 月）
RJ23) 杉浦智子、加藤将夫　有機カチオントランスポーターOCTN1/SLC22A4 によるエルゴチオネイン輸送　ビタミン, **84**(10): 465-471, 2010.
RJ22) 杉浦智子、加藤将夫
メタボロミクスによる orphan SLC トランスポーターの生体内基質探索
医薬のあゆみ, **231**(12,13): 1176-1182, 2009.
RJ21) 杉浦智子、加藤将夫
薬物動態関連トランスポーターと相互作用するタンパク質

遺伝子医学 MOOK (12) 最新トランスポーター研究 2009、杉山雄一・金井好克編
株式会社メディカルドゥ、pp. 76-82（2009 年 1 月）

RJ20) 杉浦智子，加藤将夫，辻　彰
膜トランスポーターとタンパク質間相互作用
生体の科学，**58**, 412-414, 2007.

RJ19) 加藤将夫、内海理恵、辻　彰
薬物輸送を制御するアダプタータンパク質
遺伝子医学 MOOK (7) 最新創薬学 2007、杉山雄一編
株式会社メディカルドゥ、pp.142-148（2007 年 4 月）

RJ18) 加藤将夫
トランスポーター・アダプターを介した栄養物・薬物の生体膜透過
薬剤学 **67**(1): 27-31, 2007.

RJ17) 加藤将夫、松本　健、辻　彰
薬物トランスポーターと薬剤感受性(1) -薬物トランスポーターの遺伝的多型とその評価-
最新医学 **60**(9): 1819-1826, 2005.

RJ16) 加藤将夫、辻　彰
糖のトランスポーター，レセプター
Drug Delivery System **19**(1): 38-44, 2004.

RJ15) 加藤将夫、杉山雄一
ファーマコキネティクスの立場からみたターゲティングの設計
Drug Delivery System **16**(5): 376-383, 2001.

RJ14) 加藤将夫、杉山雄一
Pharmacogenomics/Pharmacogenetics に基づく適正化学療法
Bio Clinica **15**(13): 1028-1032, 2000.

RJ13) 杉山雄一、加藤将夫
遺伝子多型と抗癌剤の効果・副作用
Cancer Frontier **2**(1): 21-27, 2000.

RJ12) 杉山雄一、加藤将夫、金光真一、伊藤清美
肝臓での代謝および輸送における薬物間相互作用の定量的予測
薬物動態 **15**(3): 235-243, 2000.

RJ11) 設楽悦久、加藤将夫、伊藤清美、伊藤智夫、杉山雄一
薬物の輸送過程における薬物間相互作用 : 肝臓への取り込み過程における薬物間相互作用
Pharm Tech Japan. **14**(13): 2005-2016, 1998.

RJ10) 前田和哉、加藤将夫、杉山雄一
阻害剤を用いた細胞内輸送機構の解明と制御
生体の科学 **50**(6): 539-547, 1999.

RJ9) 加藤将夫、杉山雄一
薬物の輸送過程における薬物間相互作用：胆管側膜透過過程における薬物間相互作用(1)(2)
Pharm Tech Japan. **15**(1): 45-58, 1999; **15** (2): 173-185, 1999.

RJ8) 杉山雄一、新沼佳世子、申　豪徹、山田　禎、加藤将夫、中村立二、 樋坂章博
有機アニオン性低分子ペプチドの肝における輸送
肝臓病学の最前線、中外医学社、pp. 269-274、1997.

RJ7) 加藤将夫、杉山雄一
レセプター介在性エンドサイトーシスによるサイトカイン類の血中レベルの調節
RADIOISOTOPES **46**(9): 693-694, 1997.

RJ6) 加藤将夫、杉山雄一
バイオ医薬品とは
薬局 **48**(5): 714-721, 1997.

RJ5) 杉山雄一、加藤将夫、鈴木洋史

Drug Delivery System (DDS)と肝臓
肝臓病学の進歩 第 23 巻別冊: 18-25, 1997.

RJ4) 加藤将夫、泉　高司、湯浅博昭、杉山雄一
薬物動態演習　医薬品開発におけるファーマコキネティクス研究の役割３：アニマルスケールアップ
Pharm Tech Japan **12** (12): 1645-1663, 1996.

RJ3) 加藤将夫、杉山雄一
薬毒物のわかりやすい体内動態 -1, 2, 3-
中毒研究 **7**: 395-403, 1994; **8**: 85-97, 1995; **8**: 163-178, 1995.

RJ2) 加藤将夫、寺崎哲也、杉山雄一
発癌に関するリスクアセスメント：トキシコキネティクス、トキシコダイナミクスの観点から
J Toxicol Sci. **19**, Appendix 111-124, 1994.

RJ1) 加藤将夫、杉山雄一
レセプターを用いたターゲッティング
ファルマシア **29**(11): 1264-1268, 1993.

3-1. Books

B9) Masuo Y, Futatsugi A, Kato Y. Experimental approaches for studying drug transporters. In: “Drug Transporters,” edited by You G and Morris ME, John Wiley& Sons, Inc., Hoboken, NJ, pp413-431, 2022.

B8) Ishimoto T, Kato Y. Regulation of neurogenesis by organic cation transporters: Potential therapeutic implications. In: “Organic Cation Transporters in the Central Nervous System (Part of the Handbook of Experimental Pharmacology book series),” edited by Daws LC, Springer Nature, pp281–300, 2021.

B7) Kubo Y, Tsuji A, Kato Y. Experimental approaches to the study of drug transporters. In: “Drug Transporters,” edited by You G and Morris ME, John Wiley& Sons, Inc., Hoboken, NJ, pp355-369, 2014.

B6) Sugiura T, Umeda S, Tsuji A, Kato Y. PEPT (SLC15A) family. In: "Pharmacogenomics of Human Drug Transporters," edited by Ishikawa T, Kim RB, König J, Aptara Inc., pp223-242, 2013.

B5) Kubo Y, Kato Y, Tsuji A. Experimental approaches to the study of drug transporters. In: “Drug Transporters,” edited by You G and Morris ME, John Wiley& Sons, Inc., Hoboken, NJ, pp533-556, 2007.

B4) Haas M, Kato Y, Haverdings RFG, Moolenaar F, Suzuki K, de Zeeuw D, Sugiyama Y, Meijer DKF. Delivery of drugs and antisense oligonucleotides to the proximal tubular cell of the kidney using macromolecular and pro ‐ drug approaches. In: "Drug Targeting: Organ ‐ specific strategies," edited by Molema G and Meijer DKF, Wiley ‐ VCH, pp121-155, 2001.

B3) Sugiyama Y, Kato Y. Tissue selective drug delivery utilizing transporters and receptors. In "Biomaterials and Drug Delivery toward New Millenium," edited by Park KD, Kwon IC, Yui N, Jeong SY and Park K, Han Rim Won Publishing Co., Korea, pp383-393, 2000.

B2) Sugiyama Y, Kato Y. Receptor-mediated targeting of peptides and proteins. In:"Advanced Biomaterials in Biomedical Engineering and Drug Delivery Systems," edited by Ogata N, Kim SW, Feijen J, Okano T, Springer-Verlag Tokyo, Japan, pp121-125, 1996.

B1) Sugiyama Y, Kato Y. In vitro models of hepatic uptake: Methods to determine kinetic parameters for receptor-mediated hepatic uptake. In: "Peptide-Based Drug Design: Controlling Transport and Metabolism," edited by Taylor MD and Amidon GL, American Chemical Society Books Department, Washington DC, USA, pp525-551, 1995.

3-2. Books 著書（和文）

BJ10)山下怜矢、長瀬乃愛、加藤将夫
食物由来水溶性アミノ酸エルゴチオネインによる認知機能改善効果

食品機能性成分の吸収・代謝・作用機序Ⅱ
シーエムシー出版、pp.53- 61（2025 年 10 月）

BJ9) 加藤将夫
第 9 章「酵素以外のタンパク質」
新スタンダード薬学シリーズ 第三巻　新スタ薬シリーズ編集委員会　編
東京化学同人、pp.182-190（2024 年 3 月 31 日）

BJ8) 核酸の分子栄養学
加藤久典、加藤将夫編
エヌ・ティー・エス、202 ページ（2019 年 5 月 17 日）

BJ7) 加藤将夫、辻　彰
トランスポーターの細胞内局在メカニズムと薬物動態変動への影響
分子薬物動態学　杉山雄一、楠原洋之編
南山堂、pp.395-410（2008 年 4 月）

BJ6) 加藤将夫
薬物トランスポーターの上皮細胞頂側膜発現調節に機能するタンパク質の生理・薬理学的役割
トランスポーター科学最前線　辻　彰編
京都廣川書店、pp.57-70（2008 年 2 月）

BJ5) 松下　良、加藤将夫
新しい剤形：ドラッグデリバリーシステム
新薬剤学（改訂第２版）　辻　彰編
南江堂、pp.359-382（2007 年 4 月）

BJ4) 加藤将夫
トランスポータータンパク質相互作用と活性調節
創薬動態：医薬品創製のための考え方と最新情報、玉井郁巳編
日本薬物動態学会、pp.169-175（2006 年 12 月）

BJ3) 加藤将夫、杉山雄一
レセプター・トランスポーターと薬物ターゲティング
今日のＤＤＳ　薬物送達システム　高橋俊雄、橋田　充編集
医薬ジャーナル社、pp.137-148 (1999 年 12 月).

BJ2) 加藤将夫、杉山雄一
G-CSF 併用による化学療法と biochemical response modifiers (BRM) 療法
抗癌剤の相互作用：これからの抗癌剤治療戦略、杉山雄一・佐々木康綱編、
医薬ジャーナル社、pp.80-89 (1998 年 1 月).

BJ1) 加藤将夫
アニマルスケールアップ
医薬品開発における薬物動態研究、杉山雄一編、薬業時報社、101-168 (1998 年 3 月).

---

4. Editorial and Preface　序文

E3) Kato Y. Efforts to overcome in vitro/in vivo discrepancy. Editorial. ***Drug Metab Pharmacokinet*** 24(5): 409-410, 2009.

E2) Kato Y, Tamai I. New aspects of transporter research: future may exist "beyond the transport". Preface. ***Drug Metab Pharmacokinet*** 23(4): 221-222, 2008.

E1) Kawai R, Chiba M, Hashimoto Y, Hosokawa M, Kato Y, Nagata K, Tamai I. Half-way achievement with “DMPK Globalization Committee”; What had been and what is to be done for further globalization. Editorial. ***Drug Metab Pharmacokinet*** 22(1): 1–2, 2007.

5. Others　紹介文、啓蒙書

O2) 加藤将夫
　薬剤学を基盤とする薬物治療学
　薬剤学 **70**(2): 109-114, 2010.

O1) 加藤将夫
　初心者のための動態関連論文投稿のノウハウ
　日本薬物動態学会ニュースレター　**21**(3): 14-19, 2006.